Current evidence suggests that patients with Luminal A early breast cancer can skip chemotherapy or extended endocrine therapy, but immunohistochemistry-based biomarker analysis for St Gallen subtyping may not be reproducible. We asked whether RT-qPCR can be used instead to address this clinical question. | Impact of molecular subtypes on the prediction of distant recurrence in estrogen receptor ER positive human epidermal growth factor receptor 2 HER2 negative breast cancer upon five years of endocrine therapy
